Recent advances in immunostimulatory CpG oligonucleotides

Current Opinion in Molecular Therapeutics

Volumn 5, Issue 2, 2003, Pages 98-106

  Rothenfusser, Simon ^a   Tuma, Evelyn ^a   Wagner, Moritz ^a   Endres, Stefan ^a   Hartmann, Gunther ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

B cell; CpG oligodeoxynucleotide; Immunomodulation; Plasmacytoid dendritic cell; Vaccine adjuvant

Indexed keywords

ALUMINUM POTASSIUM SULFATE; ANTISENSE OLIGODEOXYNUCLEOTIDE; DNA; IMMUNOMODULATING AGENT; IMMUNOSTIMULATING AGENT; IMMUNOTOXIN; LEISHMANIA VACCINE; OBLIMERSEN; ODN 2006; ODN 2216; PHOSPHODIESTERASE; PHOSPHOROTHIOIC ACID DERIVATIVE; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; B LYMPHOCYTE; BONE DISEASE; CANCER; CANCER IMMUNOTHERAPY; CENTRAL NERVOUS SYSTEM INFECTION; CLINICAL TRIAL; COLITIS; CPG ISLAND; DENDRITIC CELL; DRUG MECHANISM; DRUG POTENCY; GENITAL HERPES; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOGENICITY; LEISHMANIASIS; LYMPHOCYTE SUBPOPULATION; MOLECULAR RECOGNITION; MOUSE; NONHUMAN; PRION DISEASE; PROTEIN MOTIF; REVIEW; VERTEBRATE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; B-LYMPHOCYTES; CPG ISLANDS; DENDRITIC CELLS; DNA-BINDING PROTEINS; HUMANS; INTERFERON TYPE II; KILLER CELLS, NATURAL; MICE; MONOCYTES; OLIGONUCLEOTIDES; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TOLL-LIKE RECEPTOR 9;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; VERTEBRATA;

EID: 0038814164     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Wagner H: Interactions between bacterial CpG-DNA and TLR9 bridge innate and adaptive immunity. Curr Opin Microbiol (2002) 5(1):62-69.
2. Bauer S, Wagner H: Bacterial CpG-DNA licenses TLR9. Curr Top Microbiol Immunol (2002) 270:145-154.
3. Krieg AM: A role for toll in autoimmunity. Nat Immunol (2002) 3(5):423-424.
4. Krieg AM: CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol (2002) 20:709-760.
5. Hartmann G, Krieg AM: Mechanism and function of a newly identified CpG DNA motif in human primary B-cells. J Immunol (2000) 164(2):944-953.
6. Hartmann G, Weeratna RD, Ballas ZK, Payette P, Blackwell S, Suparto I, Rasmussen WL, Waldschmidt M, Sajuthi D, Purcell RH, Davis HL et al. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J Immunol (2000) 164(3):1617-1624.
7. Bauer S, Kirschning CJ, Hacker H, Redecke V, Hausmann S, Akira S, Wagner H, Lipford GB: Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci USA (2001) 98(16):9237-9242.
8. Chuang TH, Lee J, Kline L, Mathison JC, Ulevitch RJ: Toll-like receptor 9 mediates CpG-DNA signaling. J Leukocyte Biol (2002) 71(3):538-544.
9. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K, Akira S: A toll-like receptor recognizes bacterial DNA. Nature (2000) 408(6813):740-745.
10. Homung V, Rothenfusser S, Britsch S, Krug A, Jahrsdorfer B, Giese T, Endres S, Hartmann G: Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol (2002) 168(9):4531-4537.
11. Krug A, Towarowski A, Britsch S, Rothenfusser S, Homung V, Bals R, Giese T, Engelmann H, Endres S, Krieg AM, Hartmann G: Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur J Immunol (2001) 31(10):3026-3037.
12. Jarrossay D, Napolitani G, Colonna M, Sallusto F, Lanzavecchia A: Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells. Eur J Immunol (2001) 31(11):3388-3393.
13. Kadowaki N, Ho S, Antonenko S, Malefyt RW, Kastelein RA, Bazan F, Liu YJ: Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med (2001) 194(6):863-869.
14. Boonstra A, Asselin-Paturel C, Gilliet M, Crain C, Trinchieri G, Liu YJ, O'Garra A: Flexibility of mouse classical and plasmacytoid-derived dendritic cells in directing T helper type 1 and 2 cell development: Dependency on antigen dose and differential toll-like receptor ligation. J Exp Med (2003) 197(1):101-109.
15. Rothenfusser S, Tuma E, Endres S, Hartmann G: Plasmacytoid dendritic cells: The key to CpG. Hum Immunol (2002) 63(12):1111-1119.
16. Sandberg K, Matsson P, Alm GV: A distinct population of nonphagocytic and low level CD4+ null lymphocytes produce IFNα after stimulation by herpes simplex virus-infected cells. J Immunol (1990) 145(3):1015-1020.
17. Lennert K, Remmele W: Karyometric investigations in human lymph node cells. Acta Haemat (1958) 19:99-113.
18. Wollenberg A, Wagner M, Gunther S, Towarowski A, Tuma E, Moderer M, Rothenfusser S, Wetzel S, Endres S, Hartmann G: Plasmacytoid dendritic cells: A new cutaneous dendritic cell subset with distinct role in inflammatory skin diseases. J Invest Dermatol (2002) 119(5):1096-1102.
19. Hartmann G, Weiner GJ, Krieg AM: CpG DNA: A potent signal for growth, activation, and maturation of human dendritic cells. Proc Natl Acad Sci USA (1999) 96(16):9305-9310.
20. Kadowaki N, Antonenko S, Liu YJ: Distinct CpG DNA and polyinosinic-polycytidylic acid double-stranded RNA, respectively, stimulate CD11c- type 2 dendritic cell precursors and CD11c+ dendritic cells to produce type I IFN. J Immunol (2001) 166(4):2291-2295.
21. Krug A, Rothenfusser S, Hornung V, Jahrsdorfer B, Blackwell S, Ballas ZK, Endres S, Krieg AM, Hartmann G: Identification of CpG oligonucleotide sequences with high induction of IFNα/β in plasmacytoid dendritic cells. Eur J Immunol (2001) 31(7):2154-2163.
22. Verthelyi D, Ishii KJ, Gursel M, Takeshita F, Klinman DM: Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs. J Immunol (2001) 166(4):2372-2377.
23. Gursel M, Verthelyi D, Gursel I, Ishii KJ, Klinman DM: Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotide. J Leukocyte Biol (2002) 71(5):813-820.
24. Rothenfusser S, Hornung V, Krug A, Towarowski A, Krieg AM, Endres S, Hartmann G: Distinct CpG oligonucleotide sequences activate human γδ T-cells via Interferon-α/-β. Eur J Immunol (2001) 31(12):3525-3534.
25. Gursel M, Verthelyi D, Klinman DM: CpG oligodeoxynucleotides induce human monocytes to mature into functional dendritic cells. Eur J Immunol (2002) 32(9):2617-2622.
26. Hartmann G, Battiany J, Poeck H, Wagner M, Kerkmann M, Lubenow N, Rothenfusser S, Endres S: Rational design of new CpG oligonucleotides that combine B-cell activation with high IFNα induction in plasmacytoid dendritic cells. Eur J Immunol (2003): in press.
27. Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, Horiuchi T, Tomizawa H, Takeda K, Akira S: Small anti-viral compounds activate immune cells via the TLR7 MyD88-depandent signaling pathway. Nat Immunol (2002) 3(2):196-200.
28. Takauji R, Iho S, Takatsuka H, Yamamoto S, Takahashi T, Kitagawa H, Iwasaki H, Iida R, Yokochi T, Matsuki T: CpG-DNA-induced IFNα production involves p38 MAPK-dependent STAT1 phosphorylation in human plasmacytoid dendritic cell precursors. J Leukocyte Biol (2002) 72(5):1011-1019.
29. Kerkmann M, Rothenfusser R, Hornung V, Towarowski A, Wagner M, Sarris A, Giese T, Endres S, Hartmann G: Activation with CpG-A and CpG-B oligonucleotides reveals two distinct regulatory pathways of type I IFN synthesis in human plasmacytoid dendritic cells. J Immunol (2003) 70(9):4465-4474.
30. Jung J, Yi AK, Zhang X, Choe J, Li L, Choi YS: Distinct response of human B-cell subpopulations in recognition of an innate immune signal, CpG DNA. J Immunol (2002) 169(5):2368-2373.
31. Bernasconi NL, Traggiai E, Lanzavecchia A: Maintenance of serological memory by polyclonal activation of human memory B-cells. Science (2002) 298(5601):2199-2202.
32. Jahrsdorfer B, Hartmann G, Racila E, Jackson W, Muhlenhoff L, Meinhardt G, Endres S, Link BK, Krieg AM, Weiner GJ: CpG DNA increases primary malignant B-cell expression of costimulatory molecules and target antigens. J Leukocyte Biol (2001) 69(1):81-88.
33. Jahrsdorfer B, Jox R, Muhlenhoff L, Tschoep K, Krug A, Rothenfusser S Meinhardt G, Emmerich B, Endres S, Hartmann, G: Modulation of malignant B-cell activation and apoptosis by bcl-2 antisense ODN and immunostimulatory CpG ODN. J Leukocyte Biol(2002) 72(1):83-92.
34. Decker T, Hipp S, Kreitman RJ, Pastan I, Peschel C, Licht T: Sensitization of B-cell chronic lymphocytic leukemia cells to recombinant immunotoxin by immunostimulatory phosphorothioate oligodeoxynucleotides. Blood (2002) 99(4):1320-1326.
35. Krug S, Rothenfusser S, Selinger S, Bock C, Kerkmann M, Battiany J, Sarris A, Giese T, Speiser D, Endres S, Hartmann G: CpG-A ODN induce a monocyte-derived dendritic cell-like phenotype which preferentially activates CD8 T-cells. J Immunol (2003) 170(7):3468-3477.
36. Jones TR, Obaldia N, Gramzinski RA, Charoenvit Y, Kolodny N, Kitov S, Davis HL, Krieg AM, Hoffman SL: Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys. Vaccine (1999) 17(23-24):3065-3071.
37. Davis HL, Suparto II, Weeratna RR, Jumintarto, Iskandriati DD Chamzah SS, Ma'ruf AA, Nente CC, Pawitri DD, Krieg AM, Heriyanto et al. CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans. Vaccine (2000) 18(18):1920-1924.
38. Verthelyi D, Kenney RT, Seder RA, Gam AA, Friedag B, Klinman DM: CpG oligodeoxynucleotides as vaccine adjuvants in primates. J Immunol (2002) 168(4):1659-1663.
39. Vollmer J, Janosch A, Laucht M, Ballas ZK, Schetter C, Krieg AM: Highly immunostimulatory CpG-free oligodeoxynucleotides for activation of human leukocytes. Antisense Nucleic Acid Drug Dev (2002) 12(3):165-175.
40. Yu D, Zhu FG, Bhagat L, Wang H, Kandimalla ER, Zhang R, Agrawal S: Potent CpG oligonucleotides containing phosphodiester linkages: In vitro and in vivo immunostimulatory properties. Biochem, Biophys Res Commun (2002) 297(1):83-90.
41. Krieg AM, Wu T, Weeratna R, Efler SM, Love-Homan L, Yang L, Yi AK, Short D, Davis HL: Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. Proc Natl Acad Sci USA (1998) 95(21):12631-12636.
42. Stunz LL, Lenert P, Peckham D, Yi AK, Haxhinasto S, Chang M, Krieg AM, Ashman RF: Inhibitory oligonucleotides; specifically block effects of stimulatory CpG oligonucleotides in B-cells. Eur J Immunol (2002) 32(5):1212-1222.
43. Yamada H, Gursel I, Takeshita F, Conover J, Ishii KJ, Gursel M, Takeshita S, Klinman DM: Effect of suppressive DNA on CpG-induced Immune activation. J Immunol (2002) 169(10):5590-5594.
44. Zeuner RA, Ishii KJ, Lizak MJ, Gursel I, Yamada H, Klinman DM, Verthelyi D: Reduction of CpG-induced arthritis by suppressive oligodeoxynucleotides. Arthritis Rheum (2002) 46(8):2219-2224.
45. Ahmad-Nejad P, Hacker H, Rutz M, Bauer S, Vabulas RM, Wagner H: Bacterial CpG-DNA and lipopolysaccharides activate toll-like receptors at distinct cellular compartments. Eur J Immunol (2002) 32(7):1958-1968.
46. Chu W, Gong X, Li Z, Takabayashi K, Ouyang H, Chen Y, Lois An, Chen DJ, Li GC, Karin M, Raz E: DNA-PKcs is required for activation of innate immunity by immunostimulatory DNA. Cell (2000) 103(6):909-918.
47. Ishii KJ, Takeshita F, Gursel I, Gursel M, Conover J, Nussenzweig A, Klinman DM: Potential role of phosphatidylinositol 3 kinase, rather than DNA-dependent protein kinase, in CpG DNA-induced immune activation. J Exp Med (2002) 196(2):269-274.
48. Miconnet I, Koenig S, Speiser D, Krieg A, Guillaume P, Cerottini JC, Romero P: CpG are efficient adjuvants for specific CTL Induction against tumor antigen-derived peptide. J Immunol (2002) 168(3):1212-1218.
49. Maurer T, Heit A, Hochrein H, Ampenberger F, O'Keeffe M, Bauer S, Lipford GB, Vabulas RM, Wagner H: CpG-DNA aided cross-presentation of soluble antigens by dendritic cells. Eur J Immunol (2002) 32(8):2356-2364.
50. Shirota H, Sano K, Hirasawa N, Terui T, Ohuchi K, Hattori T, Tamura G: B-cells capturing antigen conjugated with CpG oligodeoxynucleotides induce Th1 cells by elaborating IL-12. J Immunol (2002) 169(2):787-794.
51. Zou W, Schwartz H, Endres S, Hartmann G, Bar-Shavit Z: CpG oligonucleotides: Novel regulators of osteoclast differentiation. FASEB J (2002) 16(3):274-282.
52. Takeshita S, Takeshita F, Haddad DE, Janabi N, Klinman DM: Activation of microglia and astrocytes by CpG oligodeoxynucleotides. Neuroreport (2001) 12(14):3029-3032.
53. Dalpke AH, Schafer MK, Frey M, Zimmermann S, Tebbe J, Weihe E, Heeg K: Immunostimulatory CpG-DNA activates murine microglia. J Immunol (2002) 168(10):4854-4863.
54. Sethi S, Lipford G, Wagner H, Kretzschmar H: Postexposure prophylaxis against prion disease with a stimulator of innate immunity. Lancet (2002) 360(9328):229-230.
55. Rhee EG, Mendez S, Shah JA, Wu CY, Kirman JR, Turon TN, Davey DF, Davis H, Klinman DM, Coler RN, Sacks DL et al. Vaccination with heat-killed Leishmania antigen or recombinant leishmanial protein and CpG oligodeoxynucleotides induces long-term memory CD4+ and CD8+ T-cell responses and protection against Leishmania major infection. J Exp Med (2002) 195(12):1565-1573.
56. Harandi AM, Eriksson K, Holmgren J: A protective role of locally administered immunostimulatory CpG oligodeoxynucleotide in a mouse model of genital herpes infection. J Virol (2003) 77(2):953-962.
57. Pyles RB, Higgins D, Chalk C, Zalar A, Eiden J, Brown C, Van Nest G, Stanberry LR: Use of immunostimulatory sequence-containing oligonucleotides as topical therapy for genital herpes simplex virus type 2 infection. J Virol (2002) 76(22):11387-11396.
58. Dumais N, Patrick A, Moss RB, Davis HL, Rosenthal KL: Mucosal immunization with inactivated human immunodeficiency virus plus CpG oligodeoxynucleotides induces genital immune responses and protection against intravaginal challenge. J Infect Dis (2002) 186(8):1098-1105.
59. Obermeier F, Dunger N, Deml L, Herfarth H, Scholmerich J, Falk W: CpG motifs of bacterial DNA exacerbate colitis of dextran sulfate sodium-treated mice. Eur J Immunol (2002) 32(7):2084-2092.
60. Rachmilewitz D, Karmeli F, Takabayashi K, Hayashi T, Leider-Trejo L, Lee J, Leoni LM, Raz E: Immunostimulatory DNA ameliorates experimental and spontaneous murine colitis. Gastroenterology (2002) 122(5):1428-1441.
61. Sfondrini L, Besusso D, Rumio C, Rodolfo M, Menard S, Balsari A: Prevention of spontaneous mammary adenocarcinoma in HER-2/neu transgenic mice by foreign DNA. FASEB J (2002) 16(13):1749-1754.
62. Heckelsmiller K, Rall K, Beck S, Schlamp A, Seiderer J, Jahrsdorfer B, Krug A, Rothenfusser S, Endres S, Hartmann G: Peritumoral CpG DNA elicits a coordinated response of CD8 T-cells and innate effectors to cure established tumors in a murine colon carcinoma model. J Immunol (2002) 169(7):3892-3899.
63. Heckelsmiller K, Beck S, Rall K, Sipos B, Schlamp A, Tuma E, Rothenfusser S, Endres S, Hartmann G: Combined dendritic cell- and CpG oligonucleotide-based immune therapy cures large murine tumors that resist chemotherapy. Eur J Immunol (2002) 32(11):3235-3245.
64. Auf G, Chen L, Fornes P, Le Clanche C, Delattre JY, Carpentier AF: CpG-oligodeoxynucleotide rejection of a neuroblastoma in A/J mice does not induce a paraneoplastic disease. Neurosci Left (2002) 327(3):189-192,
65. Fonteneau J-F, Gilliet M, Larsson M, Dasilva I, Munz C, Liu Y-J, Bhardwaj N: Activation of influenza virus-specific CD4+ and CD8+ T-cells: A new role for plasmacytoid dendritic cells in adaptive immunity. Blood (2003):101(9):3520-3526.